S&P 500   4,220.82 (+0.98%)
DOW   33,126.20 (+0.66%)
QQQ   351.17 (+0.91%)
AAPL   179.85 (+1.47%)
MSFT   330.68 (+0.70%)
META   270.24 (+2.09%)
GOOGL   123.13 (+0.21%)
AMZN   122.49 (+1.58%)
TSLA   204.73 (+0.39%)
NVDA   394.60 (+4.30%)
NIO   7.47 (-0.80%)
BABA   82.85 (+4.15%)
AMD   119.70 (+1.26%)
T   15.81 (+0.51%)
F   12.06 (+0.50%)
MU   69.12 (+1.35%)
CGC   0.84 (+0.63%)
GE   104.65 (+3.07%)
DIS   88.52 (+0.64%)
AMC   4.61 (+2.44%)
PFE   38.06 (+0.11%)
PYPL   63.00 (+1.63%)
NFLX   402.16 (+1.75%)
S&P 500   4,220.82 (+0.98%)
DOW   33,126.20 (+0.66%)
QQQ   351.17 (+0.91%)
AAPL   179.85 (+1.47%)
MSFT   330.68 (+0.70%)
META   270.24 (+2.09%)
GOOGL   123.13 (+0.21%)
AMZN   122.49 (+1.58%)
TSLA   204.73 (+0.39%)
NVDA   394.60 (+4.30%)
NIO   7.47 (-0.80%)
BABA   82.85 (+4.15%)
AMD   119.70 (+1.26%)
T   15.81 (+0.51%)
F   12.06 (+0.50%)
MU   69.12 (+1.35%)
CGC   0.84 (+0.63%)
GE   104.65 (+3.07%)
DIS   88.52 (+0.64%)
AMC   4.61 (+2.44%)
PFE   38.06 (+0.11%)
PYPL   63.00 (+1.63%)
NFLX   402.16 (+1.75%)
S&P 500   4,220.82 (+0.98%)
DOW   33,126.20 (+0.66%)
QQQ   351.17 (+0.91%)
AAPL   179.85 (+1.47%)
MSFT   330.68 (+0.70%)
META   270.24 (+2.09%)
GOOGL   123.13 (+0.21%)
AMZN   122.49 (+1.58%)
TSLA   204.73 (+0.39%)
NVDA   394.60 (+4.30%)
NIO   7.47 (-0.80%)
BABA   82.85 (+4.15%)
AMD   119.70 (+1.26%)
T   15.81 (+0.51%)
F   12.06 (+0.50%)
MU   69.12 (+1.35%)
CGC   0.84 (+0.63%)
GE   104.65 (+3.07%)
DIS   88.52 (+0.64%)
AMC   4.61 (+2.44%)
PFE   38.06 (+0.11%)
PYPL   63.00 (+1.63%)
NFLX   402.16 (+1.75%)
S&P 500   4,220.82 (+0.98%)
DOW   33,126.20 (+0.66%)
QQQ   351.17 (+0.91%)
AAPL   179.85 (+1.47%)
MSFT   330.68 (+0.70%)
META   270.24 (+2.09%)
GOOGL   123.13 (+0.21%)
AMZN   122.49 (+1.58%)
TSLA   204.73 (+0.39%)
NVDA   394.60 (+4.30%)
NIO   7.47 (-0.80%)
BABA   82.85 (+4.15%)
AMD   119.70 (+1.26%)
T   15.81 (+0.51%)
F   12.06 (+0.50%)
MU   69.12 (+1.35%)
CGC   0.84 (+0.63%)
GE   104.65 (+3.07%)
DIS   88.52 (+0.64%)
AMC   4.61 (+2.44%)
PFE   38.06 (+0.11%)
PYPL   63.00 (+1.63%)
NFLX   402.16 (+1.75%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

$42.75
+1.85 (+4.52%)
(As of 12:09 PM ET)
Compare
Today's Range
$40.86
$42.84
50-Day Range
$33.62
$42.28
52-Week Range
$32.69
$48.82
Volume
411,177 shs
Average Volume
981,664 shs
Market Capitalization
$6.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.64

Ionis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
9.6% Upside
$46.64 Price Target
Short Interest
Bearish
5.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.21mentions of Ionis Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$286,134 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.54) to ($3.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

1787th out of 1,980 stocks

Pharmaceutical Preparations Industry

893rd out of 978 stocks


IONS stock logo

About Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
8-K: IONIS PHARMACEUTICALS INC
See More Headlines

IONS Price History

IONS Company Calendar

Last Earnings
5/03/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.64
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+14.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$-269,720,000.00
Pretax Margin
-53.18%

Debt

Sales & Book Value

Annual Sales
$587 million
Book Value
$3.40 per share

Miscellaneous

Free Float
139,723,000
Market Cap
$5.85 billion
Optionable
Optionable
Beta
0.54

Key Executives

  • Brett P. MoniaBrett P. Monia
    Chief Executive Officer & Director
  • Onaiza Cadoret-Manier
    EVP, Chief Product Strategy & Operations Officer
  • Elizabeth L. HougenElizabeth L. Hougen
    Chief Financial Officer & Executive VP-Finance
  • C. Frank Bennett
    Chief Scientific Officer & Executive VP
  • Sanjay Bhanot
    Chief Medical Officer & SVP













IONS Stock - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2023?

10 Wall Street research analysts have issued 1 year target prices for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they predict the company's stock price to reach $46.64 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2023?

Ionis Pharmaceuticals' stock was trading at $37.77 at the start of the year. Since then, IONS shares have increased by 8.3% and is now trading at $40.90.
View the best growth stocks for 2023 here
.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IONS earnings forecast
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.13. The firm had revenue of $131 million for the quarter, compared to the consensus estimate of $126.88 million. Ionis Pharmaceuticals had a negative net margin of 56.85% and a negative trailing twelve-month return on equity of 57.58%. The business's revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.46) earnings per share.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $597.65 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Clearbridge Investments LLC (3.77%), Price T Rowe Associates Inc. MD (2.75%), ARK Investment Management LLC (1.84%), BVF Inc. IL (1.79%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $40.90.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.85 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

The company employs 660 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -